Clinical Trial Update: Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and efficacy of rAAV.hCNGA3 gene therapy for CNGA3-linked Achromatopsia; trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achromatopsia

Drugs mentioned

• rAAV.hCNGA3 gene therapy (rAAV.hCNGA3)

Snippet

Sponsor: STZ eyetrial | Conditions: Achromatopsia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING